Form 4: MAIA Biotechnology Insider Trades Stock Options
Insider Transaction
MAIA Biotechnology's CEO, Vlad Vitoc, reports the acquisition of 800,000 stock options with an exercise price of $1.28, vesting over four years.
Summary
- Vlad Vitoc, CEO and Director of MAIA Biotechnology, Inc., has reported the acquisition of 800,000 stock options.
- These options have an exercise price of $1.28 per share.
- The options were granted on April 10, 2026, under the company's 2021 Equity Incentive Plan.
- Vesting occurs over a four-year schedule: 25% on the first anniversary of the grant date, with the remaining 75% vesting monthly over the subsequent 36 months.
- Vitoc is also a 10% owner of MAIA Biotechnology.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard insider stock option grant and vesting schedule rather than a significant financial event or strategic shift.
Positives
- The CEO's acquisition of stock options signals a commitment to the company's future performance.
- The vesting schedule encourages long-term engagement and alignment with shareholder interests.
Risks
- The value of the stock options is directly tied to the future performance of MAIA Biotechnology's stock price.
- If the stock price does not exceed the exercise price of $1.28, the options may not be profitable.
Future Outlook
The stock options are exercisable starting from April 10, 2027, with full vesting expected by April 10, 2030, and expire on April 10, 2036. The value realized from these options is contingent on the future stock price of MAIA Biotechnology.
Industry Context
StockSavvy.ai notes that the granting of stock options to key executives is a common practice in the biotechnology sector to incentivize performance and align management interests with those of shareholders, especially in companies focused on long-term research and development.
Stakeholder Impact
- Shareholders: The grant of options to the CEO, a 10% owner, aligns his incentives with long-term shareholder value creation, provided the stock price appreciates.
- Employees: The company's use of equity incentives may contribute to employee retention and motivation.
- Management: The CEO's personal financial stake in the company's success is increased.
Next Steps
- Vesting of stock options over a four-year period.
- Potential exercise of stock options by Vlad Vitoc, subject to vesting and market conditions.
Key Dates
| Date | Description |
|---|---|
| 04/10/2026 | Date of earliest transaction and grant date of stock options. |
| 04/10/2027 | First vesting date for 25% of the stock options. |
| 04/10/2036 | Expiration date of the stock options. |
| 04/14/2026 | Date the Form 4 was signed by the reporting person. |
Keywords
MAIA Biotechnology, Form 4, Stock Options, Insider Trading, CEO, Vlad Vitoc, Equity Incentive Plan, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.